Net Income

The financial giant sets its 2027 Investor Day. Beyond the date, it's a signal of intent for navigating a fractured world with a $4.9T balance sheet.

The eatertainment giant's profits fell, but a strategy of tech-infused games, efficient remodels, and data-driven marketing aims for a second-half revival.

As Stitch Fix shows signs of a comeback, the hiring of Sree Sreedhararaj signals a major bet on advanced AI to deepen its human-in-the-loop model.

Facing delisting, J-Star Holding bets its 50-year legacy and a high-stakes battery venture against the unforgiving mechanics of the public market.

Tsakos Energy Navigation's 36% dividend surge and $1B payout milestone underscore deep strategic resilience, capitalizing on a turbulent but profitable market.

Facing sinking sales and credit downgrades, the appliance giant is swapping cheap, short-term debt for costly long-term security. A deep dive into a bold gambit.

Defiance just launched an ETF to short the newly public SpaceX. We dive into the high-stakes gamble on a trillion-dollar titan and the perilous tools of modern trading.

A silent productivity drain is costing businesses dearly. Over half the workforce aged 40-60 is managing elder care, and the financial and career toll is immense.

Calgary's Douglas Vermeeren faces new fraud charges despite a 10-year ban. His case reveals a high-stakes battle between regulators and persistent predators.

The electric boat innovator executes another reverse stock split to stay on Nasdaq, but a history of similar moves raises questions about its financial health.

New clinical trial results for XWRAP® show a significant leap in healing diabetic ulcers, positioning Applied Biologics as a formidable player in a challenging field.

With projections of $22.7M from four new supplements, Cosmos Health is betting big on the US. But can its 'science-driven' platform deliver in a crowded market?

Facing a 'going concern' warning and collapsing revenue, Splash Beverage Group is ditching drinks for drugs. Its investment in Avicanna is a desperate, yet strategic, pivot.

Seadrill's move to replace secured debt with unsecured notes is more than a balance sheet tweak; it’s a strategic signal of renewed market confidence.

As nurses and for-profit homes enter bitter arbitration, the standoff exposes a critical flaw in long-term care: a business model at odds with its mission.

Horizon Petroleum finalizes its Polish gas acquisition with a shrewd, all-cash deal, betting on long-term profits to fuel Poland's energy independence.

A small Canadian firm's breakthrough in water technology could slash energy use in major industries. But can it overcome the hurdles to commercialization?

After 990 tense sessions and a recent strike, Colombia's energy giant secured a landmark 6-year labor deal. A look at the numbers reveals a strategic trade-off.

Amid widening losses and a squeezed consumer, the children's retailer is monetizing assets and cutting deep into its supply chain. A new team bets on it being enough.

A landmark deal for CEL-SCI’s cancer drug Multikine in Saudi Arabia isn't just about a new market; it’s a case study in national ambition and biotech finance.